-
EP3459548
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3459548
| EP3459548 - PHARMACEUTICAL COMPOSITION CONTAINING KERATIN 8 PHOSPHORYLATION INHIBITOR FOR PREVENTING OR TREATING MACULAR DEGENERATION, AND METHOD FOR SCREENING MACULAR DEGENERATION MEDICINE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.03.2020 Database last updated on 06.07.2024 | |
| Former | Request for examination was made Status updated on 22.02.2019 | ||
| Former | The international publication has been made Status updated on 25.11.2017 | Most recent event Tooltip | 13.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Konkuk University Industrial Cooperation Corp. 120, Neungdong-ro Gwangjin-gu Seoul 05029 / KR | [2019/13] | Inventor(s) | 01 /
KIM, Dong Eun (Gwangjang-dong Kumho Bestvill) 104-1004 579 Gwangnaru-ro Gwangjin-gu Seoul 04984 / KR | 02 /
BAEK, Ah Ruem (Sinseong-dong) 302 12 Sinseongnam-ro 95beon-gil Yuseong-gu Daejeon 34116 / KR | [2019/13] | Representative(s) | EP&C P.O. Box 3241 2280 GE Rijswijk / NL | [2019/13] | Application number, filing date | 17799682.4 | 18.05.2017 | [2019/13] | WO2017KR05189 | Priority number, date | KR20160061259 | 19.05.2016 Original published format: KR 20160061259 | [2019/13] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017200325 | Date: | 23.11.2017 | Language: | KO | [2017/47] | Type: | A1 Application with search report | No.: | EP3459548 | Date: | 27.03.2019 | Language: | EN | [2019/13] | Search report(s) | International search report - published on: | KR | 23.11.2017 | (Supplementary) European search report - dispatched on: | EP | 26.04.2019 | Classification | IPC: | A61K31/519, A61K31/5377, A61K31/517, A61K31/4184, G01N33/50, G01N33/53 | [2019/13] | CPC: |
A61K31/4184 (EP,KR,US);
A61K31/519 (EP,KR,US);
A61K31/18 (EP);
A61K31/352 (EP);
A61K31/4709 (EP);
A61K31/517 (EP,KR,US);
A61K31/5377 (EP,KR,US);
A61P27/02 (EP,US);
G01N33/50 (US);
G01N33/502 (KR);
G01N33/5044 (KR);
G01N33/53 (KR,US);
G01N33/533 (US);
G01N33/573 (EP);
G01N2333/912 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/13] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT INHIBITOR DER KERATIN-8-PHOSPHORYLIERUNG ZUR VORBEUGUNG ODER BEHANDLUNG VON MAKULADEGENERATION UND VERFAHREN ZUM SCREENING VON MAKULADEGENERATIONSMEDIZIN | [2019/13] | English: | PHARMACEUTICAL COMPOSITION CONTAINING KERATIN 8 PHOSPHORYLATION INHIBITOR FOR PREVENTING OR TREATING MACULAR DEGENERATION, AND METHOD FOR SCREENING MACULAR DEGENERATION MEDICINE | [2019/13] | French: | COMPOSITION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA PHOSPHORYLATION DE LA KÉRATINE 8 POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE, ET PROCÉDÉ DE CRIBLAGE D'UN MÉDICAMENT CONTRE LA DÉGÉNÉRESCENCE MACULAIRE | [2019/13] | Entry into regional phase | 13.12.2018 | Translation filed | 13.12.2018 | National basic fee paid | 13.12.2018 | Search fee paid | 13.12.2018 | Designation fee(s) paid | 13.12.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 13.12.2018 | Examination requested [2019/13] | 24.09.2019 | Amendment by applicant (claims and/or description) | 31.03.2020 | Despatch of a communication from the examining division (Time limit: M06) | 28.12.2020 | Reply to a communication from the examining division | 03.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 03.08.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 13.10.2023 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 13.10.2023 | Request for further processing filed | 13.10.2023 | Full payment received (date of receipt of payment) Request granted | 23.10.2023 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 28.12.2020 | Request for further processing filed | 28.12.2020 | Full payment received (date of receipt of payment) Request granted | 18.01.2021 | Decision despatched | Fees paid | Renewal fee | 28.05.2019 | Renewal fee patent year 03 | 25.05.2020 | Renewal fee patent year 04 | 13.05.2021 | Renewal fee patent year 05 | 26.05.2022 | Renewal fee patent year 06 | 13.10.2023 | Renewal fee patent year 07 | 13.05.2024 | Renewal fee patent year 08 | Penalty fee | Additional fee for renewal fee | 31.05.2023 | 07 M06 Fee paid on 13.10.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] - SVETLANA V. KYOSSEVA, "Targeting MAPK Signaling in Age-Related Macular Degeneration", OPHTHALMOLOGY AND EYE DISEASES 2016, (20160101), vol. 8, doi:10.4137/OED.S32200, ISSN 1179-1721, XP055581309 [X] 1-5 * abstract * DOI: http://dx.doi.org/10.4137/OED.S32200 | [A] - GUM-YONG KANG ET AL, "Exosomal Proteins in the Aqueous Humor as Novel Biomarkers in Patients with Neovascular Age-related Macular Degeneration", JOURNAL OF PROTEOME RESEARCH, (20140116), vol. 13, no. 2, doi:10.1021/pr400751k, ISSN 1535-3893, pages 581 - 595, XP055581283 [A] 1-10 * section entitled "Cytokeratins and the Epithelial Mesenchymal Transition" on page 592 * DOI: http://dx.doi.org/10.1021/pr400751k | [IP] - AHRUEM BAEK ET AL, "Autophagy and KRT8/keratin 8 protect degeneration of retinal pigment epithelium under oxidative stress", AUTOPHAGY, US, (20170103), vol. 13, no. 2, doi:10.1080/15548627.2016.1256932, ISSN 1554-8627, pages 248 - 263, XP055581282 [IP] 1-10 * abstract * DOI: http://dx.doi.org/10.1080/15548627.2016.1256932 | International search | [X]KR20090094815 (ABBOTT GMBH & CO KG [DE]) [X] 1-5 * See claims 1, 14, 25-27. *; | [A]WO2010048446 (GENENTECH INC [US], et al) [A] 1-10 * See the entire document. *; | [A]KR20140128159 (UNIV KONKUK IND COOP CORP [KR]) [A] 1-10* See the entire document. *; | [X]WO2015036512 (BAYER PHARMA AG [DE]) [X] 1-3, 5 * See the abstract; and page 50. *; | [X] - DRIDI, S. et al., "ERK1/2 Activation is a Therapeutic Target in Age-related Macular Degeneration", PNAS, (20120000), vol. 109, no. 34, pages 13781 - 13786, XP055362258 [X] 1-10 * See the abstract; pages 13782-13785; and figures 4B, 4C. * DOI: http://dx.doi.org/10.1073/pnas.1206494109 |